View Item 

Show simple item record

Phase II trial of N-methylformamide in advanced head and neck cancer
dc.contributor.authorVogel, Walter C.en_US
dc.contributor.authorForastiere, Arlene A.en_US
dc.contributor.authorNatale, Ronald B.en_US
dc.contributor.authorTakasugi, Bonnie J.en_US
dc.contributor.authorSchnur, Garyen_US
dc.date.accessioned2006-09-11T15:53:59Z
dc.date.available2006-09-11T15:53:59Z
dc.date.issued1987-06en_US
dc.identifier.citationVogel, Walter C.; Forastiere, Arlene A; Natale, Ronald B.; Takasugi, Bonnie J.; Schnur, Gary; (1987). "Phase II trial of N-methylformamide in advanced head and neck cancer." Investigational New Drugs 5(2): 203-206. <http://hdl.handle.net/2027.42/45297>en_US
dc.identifier.issn0167-6997en_US
dc.identifier.issn1573-0646en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/45297
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=3654153&dopt=citationen_US
dc.description.abstractEighteen patients with advanced epidermoid carcinoma of the head and neck were entered into a phase II trial of N-Methylformamide (NMF), 800 mg/M 2 IV daily for 5 days every 4 weeks. Seventeen patients had received prior radiation therapy and 11 were previously treated with chemotherapy. No complete or partial responses were observed. The major toxicity was gastrointestinal. Fifty percent of patients experienced nausea and vomiting or reversible hepatotoxicity with greater than a 3-fold elevation of liver enzymes. Mild reversible myelosuppression occurred in 2 patients. NMF in this dose and schedule was not a useful agent to treat recurrent epidermoid carcinoma of the head and neck.en_US
dc.format.extent233411 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherKluwer Academic Publishers; Martinus Nijhoff Publishers ; Springer Science+Business Mediaen_US
dc.subject.otherMedicine & Public Healthen_US
dc.subject.otherPharmacology/Toxicologyen_US
dc.subject.otherOncologyen_US
dc.subject.otherN-methylformamideen_US
dc.subject.otherHead and Neck Canceren_US
dc.subject.otherPhase II Trialen_US
dc.titlePhase II trial of N-methylformamide in advanced head and neck canceren_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelChemistryen_US
dc.subject.hlbsecondlevelChemical Engineeringen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbsecondlevelRadiologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.subject.hlbtoplevelEngineeringen_US
dc.subject.hlbtoplevelScienceen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Internal Medicine, Division of Hematology/Oncology, The University of Michigan Hospitial, Ann Arbor, Michigan, USA; Department of Medicine, Oncology Section, Veterans Administration Medical Center, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationumDepartment of Internal Medicine, Division of Hematology/Oncology, The University of Michigan Hospitial, Ann Arbor, Michigan, USA; Department of Medicine, Oncology Section, Veterans Administration Medical Center, Ann Arbor, Michigan, USA; Oncology Section (111E), VA Medical Center, 2215 Fuller Rd., 48105, Ann Arbor, MI, USAen_US
dc.contributor.affiliationumDepartment of Internal Medicine, Division of Hematology/Oncology, The University of Michigan Hospitial, Ann Arbor, Michigan, USA; Department of Medicine, Oncology Section, Veterans Administration Medical Center, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationumDepartment of Internal Medicine, Division of Hematology/Oncology, The University of Michigan Hospitial, Ann Arbor, Michigan, USA; Department of Medicine, Oncology Section, Veterans Administration Medical Center, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationumDepartment of Internal Medicine, Division of Hematology/Oncology, The University of Michigan Hospitial, Ann Arbor, Michigan, USA; Department of Medicine, Oncology Section, Veterans Administration Medical Center, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid3654153en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/45297/1/10637_2004_Article_BF00203547.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/BF00203547en_US
dc.identifier.sourceInvestigational New Drugsen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
10637_2004_Article_BF00203547.pdf
Size:
227.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.